Cargando…

Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice

BACKGROUND: Rabies is a viral disease that causes severe neurological manifestations both in humans and various mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jung-Eun, Shin, Hyun-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172215/
https://www.ncbi.nlm.nih.gov/pubmed/33985418
http://dx.doi.org/10.1080/01652176.2021.1930277
_version_ 1783702497584480256
author Park, Jung-Eun
Shin, Hyun-Jin
author_facet Park, Jung-Eun
Shin, Hyun-Jin
author_sort Park, Jung-Eun
collection PubMed
description BACKGROUND: Rabies is a viral disease that causes severe neurological manifestations both in humans and various mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. OBJECTIVE: As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP. METHODS: VSV/RABV-GP production was measured by sandwich ELISA. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Virus entry was quantified by measuring the luciferase levels at 18-h post-transduction. BALB/c mice (three groups of six mice each) were intraperitoneally immunized with PBS, RABA, or VSV/RABV-GP at 0 and 14 days. At 28 days post-immunization serology was performed. Statistical significance was calculated using the Holm–Sidak multiple Student’s t test. RESULTS: Mice immunized with VSV/RABV-GP produced IgM and IgG antibodies, whereas IgM titers were significantly higher in mice immunized with VSV/RABV-GP compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RAVB-GP induces the T helper cell type-2 immune bias. In addition, the average (±SD; n = 3) serum neutralization titers of the inactivated RABV and VSV/RABV-GP groups were 241 ± 40 and 103 ± 54 IU/mL, respectively CONCLUSION: Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV.
format Online
Article
Text
id pubmed-8172215
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81722152021-06-10 Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice Park, Jung-Eun Shin, Hyun-Jin Vet Q Original Article BACKGROUND: Rabies is a viral disease that causes severe neurological manifestations both in humans and various mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. OBJECTIVE: As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP. METHODS: VSV/RABV-GP production was measured by sandwich ELISA. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Virus entry was quantified by measuring the luciferase levels at 18-h post-transduction. BALB/c mice (three groups of six mice each) were intraperitoneally immunized with PBS, RABA, or VSV/RABV-GP at 0 and 14 days. At 28 days post-immunization serology was performed. Statistical significance was calculated using the Holm–Sidak multiple Student’s t test. RESULTS: Mice immunized with VSV/RABV-GP produced IgM and IgG antibodies, whereas IgM titers were significantly higher in mice immunized with VSV/RABV-GP compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RAVB-GP induces the T helper cell type-2 immune bias. In addition, the average (±SD; n = 3) serum neutralization titers of the inactivated RABV and VSV/RABV-GP groups were 241 ± 40 and 103 ± 54 IU/mL, respectively CONCLUSION: Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV. Taylor & Francis 2021-06-01 /pmc/articles/PMC8172215/ /pubmed/33985418 http://dx.doi.org/10.1080/01652176.2021.1930277 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Jung-Eun
Shin, Hyun-Jin
Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title_full Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title_fullStr Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title_full_unstemmed Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title_short Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
title_sort immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172215/
https://www.ncbi.nlm.nih.gov/pubmed/33985418
http://dx.doi.org/10.1080/01652176.2021.1930277
work_keys_str_mv AT parkjungeun immunogenicityofreplicationdeficientvesicularstomatitisvirusbasedrabiesvaccineinmice
AT shinhyunjin immunogenicityofreplicationdeficientvesicularstomatitisvirusbasedrabiesvaccineinmice